XML 63 R44.htm IDEA: XBRL DOCUMENT v3.19.2
Development, Commercialization and Supply Agreement - Additional Information (Detail)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Mar. 31, 2016
USD ($)
Feb. 28, 2015
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Item
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
License And Collaboration Agreements [Line Items]                    
Revenue recognized related to upfront and milestone payments             $ 973,000 $ 248,000    
Licenses revenue         $ 100,792,000 $ 52,643,000 174,070,000 96,561,000    
Deferred revenue         19,737,000 18,806,000 19,737,000 18,806,000 $ 20,710,000 $ 19,054,000
Licensing Revenue                    
License And Collaboration Agreements [Line Items]                    
Licenses revenue         426,000 $ 106,000 $ 973,000 248,000    
Mochida | In-licenses | Research and Development Expense                    
License And Collaboration Agreements [Line Items]                    
Upfront payment                 2,700,000  
Eddingpharm | Out-licenses                    
License And Collaboration Agreements [Line Items]                    
Non-refundable up-front received       $ 15,000,000.0            
Number of indications of the regulatory milestone events relating to the submission and approval | Item             3      
Amounts to be received upon achievement of the regulatory milestone events             $ 33,000,000.0      
Sales-based milestone event payment             120,000,000.0      
Deferred revenue         13,000,000.0   13,000,000.0   13,200,000  
Eddingpharm | Out-licenses | Licensing Revenue                    
License And Collaboration Agreements [Line Items]                    
Licenses revenue             3,000,000.0   2,800,000  
Eddingpharm | Out-licenses | Maximum                    
License And Collaboration Agreements [Line Items]                    
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone             153,000,000.0      
Amounts to be received upon achievement of the regulatory milestone events             15,000,000.0      
Sales-based milestone event payment             50,000,000.0      
Revenue recognized related to upfront and milestone payments             100,000 100,000    
Eddingpharm | Out-licenses | Minimum                    
License And Collaboration Agreements [Line Items]                    
Amounts to be received upon achievement of the regulatory milestone events             2,000,000.0      
Sales-based milestone event payment             5,000,000.0      
Eddingpharm | Out-licenses | Clinical Trial Application                    
License And Collaboration Agreements [Line Items]                    
Non-refundable milestone payment     $ 1,000,000.0              
Biologix FZCo | Out-licenses                    
License And Collaboration Agreements [Line Items]                    
Revenue recognition period of non-refundable up-front payment     10 years              
HLS | Out-licenses                    
License And Collaboration Agreements [Line Items]                    
Non-refundable up-front received   $ 5,000,000.0                
Non-refundable milestone payment $ 2,500,000 $ 2,500,000                
Revenue recognized related to upfront and milestone payments             800,000 $ 200,000    
Deferred revenue         $ 5,800,000   5,800,000   6,600,000  
Non-refundable up-front received period   6 months                
HLS | Out-licenses | Licensing Revenue                    
License And Collaboration Agreements [Line Items]                    
Licenses revenue             $ 1,700,000   $ 900,000  
HLS | Out-licenses | Maximum                    
License And Collaboration Agreements [Line Items]                    
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone   $ 57,500,000